Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 4/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723020 | 1.00 | KCNH2 (0.36) | KCNH2SLC2A1MTNR1AMTNR1B | |
| SCHEMBL2291632 | 0.86 | KCNH2 (0.38) | KCNH2SLC2A1 | |
| SCHEMBL1722989 | 0.86 | KCNH2 (0.38) | KCNH2SLC2A1 | |
| SCHEMBL2293074 | 0.84 | KCNH2 (0.39) | KCNH2SLC2A1 | |
| SCHEMBL1723512 | 0.84 | KCNH2 (0.39) | KCNH2SLC2A1 | |
| SCHEMBL1711923 | 0.84 | SLC2A1 (0.38) | KCNH2SLC2A1 | |
| SCHEMBL1722990 | 0.82 | KCNH2 (0.35) | KCNH2SLC2A1 | |
| SCHEMBL1722995 | 0.82 | KCNH2 (0.35) | KCNH2SLC2A1 | |
| SCHEMBL1711952 | 0.81 | KCNH2 (0.38) | KCNH2SLC2A1 | |
| SCHEMBL1723984 | 0.80 | KCNH2 (0.36) | KCNH2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | HRH3, OXA1L, HRH1 | KCNH2 241/4885SLC2A1 4762/4885MTNR1A 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.